Presented as a Candidate's thesis to the American Laryngological, Rhinological and Otologlcal Society, Inc.
Article first published online: 5 JAN 2009
Copyright © 1980 The Triological Society
Supplement: Aminoglycoside Ototoxicity in the Human
Volume 90, Issue Supplement S24, pages 1–19, October 1980
How to Cite
Fee, W. E. (1980), AMINOGLYCOSIDE OTOTOXICITY IN THE HUMAN. The Laryngoscope, 90: 1–19. doi: 10.1288/00005537-198010001-00001
From the Division of Otolaryngology, Stanford University Medical Center.
- Issue published online: 5 JAN 2009
- Article first published online: 5 JAN 2009
- NIH Grant. Grant Number: NS14596
- Eli Lilly and Company, Indianapolis, IN, and Bristol Laboratories, Syracuse, NY
One hundred thirty-eight patient courses of tobramycin (tobra) and gentamicin (genta) were prospectively monitored for ototoxicity using weekly audiograms and electronystag-mograms. Twice weekly drug serum levels and kidney function tests were determined. A pre, during, and post-therapy history was obtained and the results were analyzed to determine significant parameters of ototoxicity.
Statistical analysis of the data was performed using SPSS on an IBM 370/3033 computer. Tobra showed less toxicity than genta but only the difference in vestibular toxicity was statistically significant. Significant associations with toxicity included the patient developing a high temperature, total dose, low hematocrit for tobra, high hematocrit for genta, high creatinine clearance with cochlear toxicity, high creatinine with nephrotoxicity, poor condition or critically ill, and duration of therapy greater than 10 days. Non-significant parameters included dose rate (mg/kg), serum levels, age, prior noise exposure, prior aminoglycosides, prior ear infections, non-aminoglycoside ototoxic drugs, underlying disease, or total number of high risks present. Ototoxicity was independent of nephrotoxicity.